Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis
Open Access
- 1 November 2010
- journal article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 80 (10), 1478-1486
- https://doi.org/10.1016/j.bcp.2010.07.038
Abstract
No abstract availableKeywords
Funding Information
- Wellcome Trust (WT079838, WT077705, WT083481)
This publication has 32 references indexed in Scilit:
- Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African TrypanosomiasisAntimicrobial Agents and Chemotherapy, 2010
- N-myristoyltransferase inhibitors as new leads to treat sleeping sicknessNature, 2010
- Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trialThe Lancet, 2009
- Chemical and genetic validation of dihydrofolate reductase–thymidylate synthase as a drug target in African trypanosomesMolecular Microbiology, 2008
- Kinetoplastids: related protozoan pathogens, different diseasesJCI Insight, 2008
- A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomesProceedings of the National Academy of Sciences, 2008
- Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected DiseasesChemMedChem, 2008
- Target assessment for antiparasitic drug discoveryTrends in Parasitology, 2007
- Bis-Acridines as Lead Antiparasitic Agents: Structure-Activity Analysis of a Discrete Compound Library In VitroAntimicrobial Agents and Chemotherapy, 2007
- Basic local alignment search toolJournal of Molecular Biology, 1990